BioCentury on BioBusiness,
Analyst Picks & Changes
Analyst picks & changes
Published on
Monday, February 13, 2012
|
Company
|
Bank
|
Analyst
|
Coverage
|
Opinion
|
Wk
chg
|
2/10
cls
|
|
Alexion
Pharmaceuticals Inc. (NASDAQ:ALXN)
|
Baird
|
Christopher
Raymond
|
Upgrade
|
Outperform
(from neutral)
|
6%
|
$83.45
|
|
|
Deutsche
Bank
|
Robyn
Karnauskas
|
Price
target
|
Buy
|
|
|
|
|
Jefferies
|
Eun
Yang
|
Price
target
|
Hold
|
|
|
|
|
Leerink
|
Howard
Liang
|
Price
target
|
Outperform
|
|
|
|
|
Stifel,
Nicolaus
|
Stephen
Willey
|
Price
target
|
Buy
|
|
|
|
|
ThinkEquity
|
Marko
Kozul
|
Price
target
|
Buy
|
|
|
|
Raymond
also raised his target to $100 from $72 after Alexion reported 4Q11 EPS of
$0.41, beating his estimate of $0.36 and the Street's estimate of $0.34 (see
EPS Watch, A17). Alexion introduced 2012 sales guidance for Soliris
eculizumab of $1.04-1.07B, and 2012 EPS guidance of $1.60-$1.70. He believes
the guidance "will prove conservative" and raised his 2012 EPS
estimate to $1.85 from $1.72. The humanized mAb targeting complement 5 (C5)
is marketed for paroxysmal nocturnal hemoglobinuria (PNH) and atypical
hemolytic uremic syndrome (aHUS).
|
|
Karnauskas
raised her target to $92 from $78 on the earnings news. In her model, she
includes the additional Soliris indication of Shiga toxin-producing Escherichia
coli-related hemolytic uremic syndrome (STEC-HUS) and the
hypophosphatasia (HPP) compound asfotase alfa. She expects Alexion to file
for the STEC-HUS indication in 2013, and estimates revenues of $360M in 2018.
Karnauskas expects Phase II data for asfotase alfa to treat HPP this year,
and believes revenues for the fusion protein incorporating the catalytic
domain of human tissue non-specific alkaline phosphatase (TNSALP) and a
bone-targeting peptide could reach $680M in 2018.
|
233
words displayed of
1065
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]